×
About 166,178 results

JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis
https://www.medpagetoday.com/hematologyoncology/othercancers/102883

Jan 30th, 2023 - Myelofibrosis treatment with the Janus kinase (JAK) inhibitor momelotinib resulted in clinically significant improvements in symptoms and spleen response compared with danazol for symptomatic, JAK inhibitor-exposed patients with anemia and intermediate- or high-risk disease, the phase III MOMENTUM trial showed. A significantly greater proportion of patients in the momelotinib group reported a ≥...

Study: Diminished COVID Vaccine Response in Lupus
https://www.medpagetoday.com/rheumatology/lupus/102876

Jan 30th, 2023 - Patients with systemic lupus erythematosus (SLE) showed reduced antibody responses following COVID-19 vaccination, with drugs for the condition such as belimumab (Benlysta) and mycophenolate mofetil (MMF) likely to blame, researchers said. Immunoglobulin G (IgG) titers measured 2 weeks after the second dose of mRNA COVID vaccines were lower by about 20% among 342 lupus patients compared with th...

The prognostic value and immune correlation of IL18 expression and promoter methylation...
https://doi.org/10.1186/s13148-023-01426-8
Clinical Epigenetics; Wang X, Zhu W et. al.

Jan 29th, 2023 - Renal cell carcinoma (RCC) is not sensitive to immunotherapy and has poor prognosis. DNA methylation regulates gene expression, and its abnormal changes are related to many human diseases. Recently, DNA methylation has been found to participate in immune infiltration in various cancers. However, its pattern in RCC remains poorly understood. We found that IL18 was significantly over-expressed in...

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia:...
https://doi.org/10.1080/17512433.2023.2174523
Expert Review of Clinical Pharmacology; Solana-Altabella A, Megías-Vericat JE et. al.

Jan 29th, 2023 - FLT3 inhibitors (FLT3i) are drugs in which there is limited experience and not yet enough information on the mechanisms of absorption, transport, and elimination; but especially on the potential drug-drug interactions (DDIs). There are therefore risks in the management of FLT3i DDIs (i.e., sorafenib, ponatinib, crenolanib, midostaurin, quizartinib, and gilteritinib) and ignoring them can compro...

Autophagy and podocytopathy.
https://doi.org/10.1093/ndt/gfad024
Nephrology, Dialysis, Transplantation : Official Publicat... Ponticelli C, Moroni G et. al.

Jan 29th, 2023 - Autophagy is a complex process of lysosomal-dependent degradation of unwanted cellular material. In response to endogenous or exogenous stimuli, autophagy is induced and regulated by two kinases: the AMP activated kinase (AMPK) and the mammalian target of rapamycin (mTOR). Cells activated by Unc-51-like kinase 1 (ULK1) form a double membrane complex that sequesters the cargo (phagophore) and el...

Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Ca...
https://doi.org/10.1097/TP.0000000000004459
Transplantation Ferrándiz-Pulido C, Leiter U et. al.

Jan 28th, 2023 - Use of immune checkpoint inhibitors (ICIs) in solid organ transplant recipients (SOTRs) with advanced skin cancers presents a significant clinical management dilemma. SOTRs and other immunosuppressed patients have been routinely excluded from ICI clinical trials with good reason: immune checkpoints play an important role in self- and allograft-tolerance and risk of acute allograft rejection rep...

Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacte...
https://doi.org/10.1021/acsinfecdis.2c00537
ACS Infectious Diseases; Stampolaki M, Malwal SR et. al.

Jan 28th, 2023 - SQ109 is a tuberculosis drug candidate that has high potency against Mycobacterium tuberculosis and is thought to function at least in part by blocking cell wall biosynthesis by inhibiting the MmpL3 transporter. It also has activity against bacteria and protozoan parasites that lack MmpL3, where it can act as an uncoupler, targeting lipid membranes and Ca2+ homeostasis. Here, we synthesized 18 ...

Response of Central Giant Cell Granuloma of the Jaw to Imatinib.
https://doi.org/10.1097/MPH.0000000000002608
Journal of Pediatric Hematology/oncology; Tallent B, Padilla RJ et. al.

Jan 28th, 2023 - Central giant cell granuloma of the jaw (CGCJ) can be locally aggressive and result in facial and dental deformity. A child with CGCJ was treated surgically and with denosumab with a response but life-threatening toxicity. Imatinib, a tyrosine kinase inhibitor, was prescribed based on clinical similarities between CGCJ and cherubism, for which Imatinib has been effective. Within 2 months, a com...

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tu...
https://doi.org/10.1200/JCO.22.02270
Journal of Clinical Oncology : Official Journal of the Am... Brahmer JR, Drake CG et. al.

Jan 28th, 2023 - Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates. Thirty-nine patients with advanced metastatic me...

Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpo...
https://doi.org/10.1007/s00262-023-03381-y
Cancer Immunology, Immunotherapy : CII; Friedman JS, Jun T et. al.

Jan 28th, 2023 - While immune checkpoint inhibitors (ICI) have had success with various malignancies, their efficacy in brain cancer is still unclear. Retrospective and prospective studies using PD-1 inhibitors for recurrent glioblastoma (GBM) have not established survival benefit. This study evaluated if ICI may be effective for select patients with recurrent GBM. This was a single-center retrospective study o...

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-p...
https://doi.org/10.1007/s00432-022-04562-5
Journal of Cancer Research and Clinical Oncology; Atallah E, Mauro MJ et. al.

Jan 28th, 2023 - The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML) is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML failing ≥ 2 lines of treatment, partly due to the paucity of head-to-head trials evaluating TKIs. Thus, matching-adjusted indirect comparisons (MAICs) were conducted to compare asciminib with competing TKIs in third- or later lin...

Management of children and adolescents with chronic myeloid leukemia in blast phase: In...
https://doi.org/10.1038/s41375-023-01822-2
Leukemia Sembill S, Ampatzidou M et. al.

Jan 28th, 2023 - Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on numerous clinical trials are available for chronic phase disease. However for CML in the blast phase (CML-BP), prognosis remains poor and treatment options are much more limited. The spectrum of treatment strategies for children and adole...

Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma:...
https://doi.org/10.1097/MD.0000000000032697
Medicine Chen X, Li D et. al.

Jan 28th, 2023 - Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are commonly used in the treatment of advanced non-small cell lung cancer. However, patients will inevitably develop resistance to EGFR-TKIs in the long-term treatment process. In this paper, we report a case of small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma. We summarize the characte...

Association between HMGA1 and immunosuppression in hepatocellular carcinoma: A comprehe...
https://doi.org/10.1097/MD.0000000000032707
Medicine Zhu J, Zheng Y et. al.

Jan 28th, 2023 - The high mobility group A1 (HMGA1) gene is overexpressed in malignant tumors, and its expression level correlates with the progression and metastasis of tumors. However, the specific role of HMGA1 in hepatocellular carcinoma (HCC) and relevant influencing approaches in tumor immunity remain unclear. In this study, the expression and clinical significance of HMGA1 in HCC immunity were analyzed. ...

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist that Modulates B Lymphocytes and P...
https://doi.org/10.1002/art.42462
Arthritis & Rheumatology (Hoboken, N.J.); Evans LS, Lewis KE et. al.

Jan 28th, 2023 - Dysregulated APRIL/BAFF signaling is implicated in the pathogenesis of multiple autoimmune diseases, including SLE and LN. A high affinity APRIL/BAFF antagonist was developed to overcome the clinical limitations of existing B cell inhibitors. A variant of TACI-Fc generated by directed evolution showed enhanced binding for both APRIL and BAFF and was designated povetacicept (ALPN-303). Povetacic...

Myeloid neoplasms post PARP inhibitors for ovarian cancer.
https://doi.org/10.1136/ijgc-2022-004190
International Journal of Gynecological Cancer : Official ... Caruso G, Gigli F et. al.

Jan 28th, 2023 - The incidence of myeloid neoplasms following treatment with poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with ovarian cancer has been gradually increasing over the last few years. The cumulative exposure to PARPi and the improved overall survival of patients with ovarian cancer may represent key underlying explanations behind such trend. Fortunately, the earlier introduction of P...

PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (AD...
https://doi.org/10.1136/ijgc-2022-003990
International Journal of Gynecological Cancer : Official ... Chelariu-Raicu A, Trillsch F et. al.

Jan 28th, 2023 - The past 5 years have seen several fundamental advances in ovarian cancer, with important new insights towards novel therapeutic opportunities within the DNA repair pathway. With the incorporation of poly (ADP-ribose) polymerase inhibitors (PARPi) into maintenance treatment regimens, the management of short- and long-term adverse events are key clinical priorities. Currently, three different PA...

Adding SBRT to sorafenib boosts survival in liver cancer
https://www.mdedge.com/hematology-oncology/article/260884/gastrointestinal-cancer/adding-sbrt-sorafenib-boosts-survival
Roxanne Nelson, RN, BSN

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved both overall survival and progression-free survival (PFS).

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

Jan 27th, 2023 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but more common in the relapsed/refractory population due to its poor prognosis and response to standard purine analog chemotherapy. HCLv cells are CD25-neg...

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
https://clinicaltrials.gov/ct2/show/NCT02658981

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safel...